We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

124 hedge funds and large institutions have $119M invested in Ventyx Biosciences in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 45 increasing their positions, 27 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 27

40% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 20

5% more funds holding

Funds holding: 118124 (+6)

2.74% more ownership

Funds ownership: 74.26%77% (+2.7%)

4% more capital invested

Capital invested by funds: $114M → $119M (+$4.83M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

43% less call options, than puts

Call options by funds: $232K | Put options by funds: $408K

Holders
124
Holders Change
+6
Holders Change %
+5.08%
% of All Funds
1.63%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
28
Increased
45
Reduced
27
Closed
20
Calls
$232K
Puts
$408K
Net Calls
-$176K
Net Calls Change
-$202K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$9.86M -$928K -409,675 -8%
Citadel Advisors
2
Citadel Advisors
Florida
$9.81M +$60K +26,457 +0.6%
Bank of America
3
Bank of America
North Carolina
$9.36M +$7.65M +3,376,446 +376%
SCM
4
Sio Capital Management
New York
$8.86M +$4.7M +2,074,849 +105%
UBS Group
5
UBS Group
Switzerland
$8.28M +$5.86M +2,585,197 +216%
Vanguard Group
6
Vanguard Group
Pennsylvania
$7.68M +$91.5K +40,366 +1%
TCM
7
Tang Capital Management
California
$6.79M
Morgan Stanley
8
Morgan Stanley
New York
$5.5M +$4.94M +2,178,199 +655%
VPC
9
Vestal Point Capital
New York
$4.38M +$623K +275,000 +16%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$3.9M +$4.04M +1,782,007 New
Goldman Sachs
11
Goldman Sachs
New York
$3.31M -$961K -424,273 -22%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.1M +$48.4K +21,337 +2%
Millennium Management
13
Millennium Management
New York
$2.81M +$2.29M +1,008,760 +370%
State Street
14
State Street
Massachusetts
$2.66M +$61.8K +27,262 +2%
IC
15
Ikarian Capital
Texas
$2.39M +$2.04M +899,943 +467%
SFM
16
Sphera Funds Management
Israel
$2.22M
JP Morgan Chase
17
JP Morgan Chase
New York
$2.03M -$179K -78,930 -8%
Connor, Clark & Lunn Investment Management (CC&L)
18
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.91M +$928K +409,357 +89%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$1.75M +$760K +335,400 +72%
Renaissance Technologies
20
Renaissance Technologies
New York
$1.37M +$704K +310,800 +99%
DM
21
Deerfield Management
New York
$1.17M -$14M -6,180,764 -92%
Charles Schwab
22
Charles Schwab
California
$1.07M +$8.19K +3,616 +0.7%
Northern Trust
23
Northern Trust
Illinois
$1.06M +$45.3K +19,982 +4%
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$1.05M -$202K -89,267 -16%
Walleye Capital
25
Walleye Capital
New York
$1.05M +$199K +87,686 +22%

VTYX Hedge Fund Activity: Q4 2024 in Review

124 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2024, worth a combined $119M — up 4.2% from $114M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VTYX positions and 20 closed out — a net gain of 8 holders — while 45 added to existing stakes and 27 trimmed.

The largest buyer was Bank of America, adding an estimated $7.65M. The largest seller was Deerfield Management, cutting an estimated $14M.

  • 124 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2024, up from 118 in Q3 2024.
  • Funds reported $119M of Ventyx Biosciences stock for Q4 2024, up 4.2% quarter-over-quarter.
  • 28 funds opened new Ventyx Biosciences positions in Q4 2024 and 20 closed out, a net change of +8 holders.
  • The largest Ventyx Biosciences buyer in Q4 2024 was Bank of America, an estimated $7.65M added.
  • The largest Ventyx Biosciences seller in Q4 2024 was Deerfield Management, an estimated $14M sold.

Based on aggregated 13F filings for Q4 2024.